156 recruiting. 156 Phase 2, 51 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 156 | Recruiting 156 |
| Phase 1 | 51 | Recruiting 51 |
| Phase 3 | 3 | Recruiting 3 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer CMF Regimen, Paclitaxel - Adenocarcinoma of the Breast, Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 76 | 2026-08-11 | 2026-08-17 |
| Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Epirubicin and cyclophosphamide followed by paclitaxel oral solution - Triple -Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-30 | 2026-08-04 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer BEBT-209 capsules, Carboplatin Injection, Gemcitabine Hydrochloride for Injection - Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 / Phase 3 | Recruiting | BeBetter Med Inc | 446 | 2026-06-04 | 2026-08-18 |
| Intratumoral N17350 in Advanced Solid Tumors N17350 - Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative | Phase 1 / Phase 2 | Recruiting | Onchilles Pharma Inc | 275 | 2026-05-25 | 2026-10-21 |
| QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ） - TNBC, Triple Negative Breast Cancer | Phase 2 | Recruiting | Jiangsu Cancer Institute & Hospital | 34 | 2026-04-17 | 2026-05-22 |
| Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer Biolosion (oral probiotic compound preparation) - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Sun Yat-sen University | 192 | 2026-04-01 | 2026-04-01 |
| A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma - Triple Negative Breast Cancer Metastatic, Melanoma Metastatic | Phase 2 | Recruiting | Fudan University | 95 | 2026-03-30 | 2026-07-13 |
| A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 20 | 2026-03-24 | 2026-08-04 |
| Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 32 | 2026-03-17 | 2026-04-27 |
| FMD and Neoadjuvant Chemo-immunotherapy in TNBC Fasting-mimicking diet, Chemotherapy, Toripalimab - Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 80 | 2026-03-05 | 2026-04-21 |
| Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 30 | 2026-03-03 | 2026-04-24 |
| Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide - Advanced Unresectable, Metastatic | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 72 | 2026-03-02 | 2026-04-13 |
| Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) Serplulimab, Paclitaxel, Carboplatin - Triple Negative Breast Cancer | Phase 2 | Recruiting | RenJi Hospital | 46 | 2026-03-01 | 2026-05-13 |
| PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing - Breast Cancer, Residual Disease | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 78 | 2026-02-26 | 2026-04-22 |
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer Immunotherapy combined with chemotherapy - Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2026-02-25 | 2026-03-02 |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors 177Lu-BetaBart, BetaBart + unlabeled BetaBart - Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 61 | 2026-02-23 | 2026-10-01 |
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
Showing 20 of 156. Sign in to see all of them.
Breast Neoplasms (59) · Carcinoma, Non-Small-Cell Lung (20) · Squamous Cell Carcinoma of Head and Neck (15) · Ovarian Neoplasms (14) · Neoplasm Metastasis (11) · Colorectal Neoplasms (10) · Carcinoma, Renal Cell (9) · Endometrial Neoplasms (9) · Melanoma (9) · Uterine Cervical Neoplasms (8) · Neoplasms (7) · Lung Neoplasms (6) · Fallopian Tube Neoplasms (5) · Head and Neck Neoplasms (5)
Breast Diseases (156) · Neoplasms by Site (156) · Skin Diseases (156) · Skin and Connective Tissue Diseases (156) · Neoplasms (149) · Breast Neoplasms (97) · Neoplasms by Histologic Type (27) · Neoplasms, Glandular and Epithelial (24) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Lung Diseases (23) · Respiratory Tract Diseases (23) · Respiratory Tract Neoplasms (23) · Thoracic Neoplasms (23) · Urogenital Diseases (23)
pembrolizumab (34) · Carboplatin (27) · Cyclophosphamide (16) · Paclitaxel (16) · Capecitabine (11) · sacituzumab govitecan (11) · 130-nm albumin-bound paclitaxel (9) · Bevacizumab (8) · Epirubicin (8) · Specimen Handling (8) · Drug Therapy (7) · Magnetic Resonance Spectroscopy (7) · Taxes (7) · durvalumab (7) · toripalimab (7)
Fudan University (11) · Memorial Sloan Kettering Cancer Center (4) · Beijing Biotech (3) · Bristol-Myers Squibb (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Sun Yat-sen University (3) · UNC Lineberger Comprehensive Cancer Center (3) · Cancer Research UK (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · First Affiliated Hospital of Zhejiang University (2) · Gilead Sciences (2) · Hebei Medical University Fourth Hospital (2) · M.D. Anderson Cancer Center (2)
United States (69) · China (53) · Australia (12) · United Kingdom (11) · France (10) · Spain (10) · Canada (8) · Japan (8) · Italy (6) · Belgium (5) · South Korea (5) · Germany (4) · Israel (4) · Netherlands (3) · Portugal (3)
Cuizhi Geng, M.D. (2) · Kamran Ahmed, MD (2) · Soo Chin Lee (2) · Yuan Yuan, MD (2) · Zefei Jiang, M.D. (2) · Zhenzhen Liu (2) · Zhimin Shao, M.D. (2) · Zhimin Shao, Professor (2) · Abi Siva, MD (1) · Abirami Sivapiragasam, MD (1) · Adriana Kahn, MD (1) · Aleix Prat (1) · Amy Xu, MD, PhD (1) · Ana C Garrido-Castro, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 30345906, PMID 30627694, PMID 30689707, PMID 32031889, PMID 32053137, PMID 32101663, PMID 32450725, PMID 32701140, PMID 32966830, PMID 33207944, PMID 34529000, PMID 34625424, PMID 34741021, PMID 35623341, PMID 35728046, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37294948, PMID 37315579, PMID 37325931, PMID 37505107, PMID 37593227, PMID 38086377, PMID 38092228, PMID 38180338, PMID 38362377, PMID 38422473, PMID 38588696, PMID 38642937, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39302614, PMID 39613746, PMID 39625569, PMID 39851040, PMID 40360463, PMID 40526879, PMID 40543428, PMID 40551254
2023 (7), 2018 (1), 2019 (1), K08CA279766 (1), P30CA012197 (1), P30CA068485 (1), P30CA138292 (1), R01CA274254 (1), R01CA290013 (1), UM1CA186704 (1)